Prognostic biomarkers in Fontan associated liver disease

Area of Science:

• Cardiology
• Hepatology
• Pediatric Medicine

Background:

• Fontan-associated liver disease (FALD) is an inevitable complication of Fontan circulation, increasing patient morbidity.
• Current methods for assessing FALD outcomes lack sensitivity, complicating clinical management.

Purpose of the Study:

• To review current prognostic tools for Fontan-associated liver disease.
• To highlight limitations of existing methods and discuss emerging risk stratification strategies.

Main Methods:

• Review of existing literature on Fontan-associated liver disease prognostication.
• Discussion of histological findings, imaging techniques (MRE), and serum biomarkers (APRI, FIB-4, MELD-XI).
• Exploration of novel risk calculators like FALD and FonLiver score.

Main Results:

• Liver biopsy is the gold standard but has limitations (invasiveness, sampling bias).
• MRE offers whole-organ assessment but lacks standardized thresholds and can be affected by hepatic congestion.
• Serum indices provide limited prognostic value; disease-specific models are needed.

Conclusions:

• Existing prognostic tools for FALD are insufficient, necessitating the development of more accurate and validated risk calculators.
• Future research should focus on prospective, multicenter pediatric studies with harmonized protocols and novel biomarkers for improved FALD management and Fontan patient outcomes.